NexImmune Bolsters Leadership Team Adding Former MedImmune Executive as Chief Financial Officer GAITHERSBURG, Md., Jan. 09, 2020 (Excerpts below were originally published on GLOBE NEWSWIRE) NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation (AIM) nanotechnology platform, announced that industry veteran John Trainer, MBA has been appointed as the [….]
NexImmune Appoints Industry Veteran Chief Medical Officer to Executive Team GAITHERSBURG, Md., Jan. 09, 2020 (originally published on GLOBE NEWSWIRE) NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation (AIM) nanotechnology platform, announced that industry veterans Han Myint, MD has been appointed as the Company’s Chief Medical Officer. Additionally, [….]
BioHealth Capital Region Startups Raised More Than $739M in 2019 These 15 Biohealth Startups had a Banner Year, Setting Themselves Up for Success in 2020 The startup ecosystem in the BioHealth Capital Region (BHCR) is as healthy as ever, as 2019 saw a host of new companies launch while still others secured important funding deals [….]
Emerging T Cell Therapy Company NexImmune Receives First IND Clearance for Phase 1/2 Trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome October 31, 2019 07:30 ET | Source: NexImmune, Inc. IND clearance enables commencement of clinical trial to evaluate NEXI-001 in AML/MDS patients with relapsed disease after allogeneic stem cell transplant IND clearance validates Company’s Artificial Immune Modulation [….]
Serial Entrepreneurs of the Biohealth Capital Region A strong group of entrepreneurs ready and willing to innovate, fund and lead new bioscience companies is essential to the creation and sustainability of top-tier biohealth clusters. It is often referenced that the BioHealth Capital Region (BHCR) lacks a deep enough pool of qualified executive talent that is [….]
